News

X-PLO₂R, a portable oxygen concentrator developed by Belluscura and its research partner Separation Design Group, has been cleared for commercialization in the U.S. The Food and Drug Administration (FDA) cleared the company’s premarket notification, or 510(k), and granted marketing authorization to the new device. Premarket notification is a formal…

A Royal Academy of Engineering Research Fellow in the U.K. has been awarded a £500,000 (nearly $700,000) grant to develop a computational model of the lung — a sort of “virtual lung” — that may be a game-changer in the development of new therapies and in the ways of caring…

Patients with chronic obstructive pulmonary disease (COPD) are more likely to develop ventricular arrhythmia, a heart rhythm disorder affecting the heart’s lower chambers or ventricles, than people without the disease, according to a Taiwanese nationwide study. Later analysis of that study also found that people with both COPD and…

Lung function and quality of life remained stable over three years of follow-up among people with chronic obstructive pulmonary disease (COPD) treated with targeted lung denervation (TLD) — a new therapy developed by Nuvaira — according to the results of a clinical trial. That trial, called AIRFLOW-1 (…

Two Montreal-based foundations are joining forces to boost research and care into complex and chronic respiratory disorders, including chronic obstructive pulmonary disease (COPD). The merging of the McGill University Health Centre (MUHC) Foundation and the Montreal Chest Institute (MCI) Foundation comes as the MUHC opens a $10 million…

A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…

The U.S. Food and Drug Administration (FDA) has cleared the start of an international pivotal trial to test the RheOx System, Gala Therapeutics’ medical device, in adults with chronic obstructive pulmonary disease (COPD) who have moderate to severe chronic bronchitis. “Chronic bronchitis is a debilitating disease which results…

Weight loss and a low body mass index (BMI) are associated with worse mortality outcomes among men with chronic obstructive pulmonary disease (COPD) in Japan, according to a new study. The study, “Low BMI and weight loss aggravate COPD mortality in men, findings from a large…

A new algorithm-based approach was developed to identify patients at risk of being misdiagnosed with chronic obstructive pulmonary disease (COPD). Researchers believe this may become an important tool to help healthcare providers in diagnosing several diseases. “Our new algorithm can find the patients who have such an unusual disease…

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…